No Data
Reported Friday, BridgeBio's Attruby Earns FDA Nod As First Therapy With ≥90% TTR Stabilization, Offering Hope For ATTR-CM Patients
Express News | Scotiabank Maintains Sector Outperform on BridgeBio Pharma, Raises Price Target to $48
Top Gap Ups and Downs on Monday: LMT, NEM, AEM and More
12 Health Care Stocks Moving In Monday's Pre-Market Session
BridgeBio Pharma Up Over 16%, on Pace for Largest Percent Increase Since July 2023 -- Data Talk
Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY (Acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis
No Data
No Data
